Evaluation of NovoRapid infusion as a treatment option in the management of diabetic ketoacidosis. Issue 11 (5th November 2017)

• Record Type: Journal Article
• Authors: Kwok, Raylene; Sztal‐Mazer, Shoshana; Hopkins, Ria E.; Poole, Susan G.; Grannell, Louise; Coutsouvelis, John; Topliss, Duncan J.
• Is Part Of: Internal medicine journal. Volume 47:Issue 11(2017)
• Page Start: 1317
• Page End: 1320
• Publication Date: 2017-11-05
• Subjects: diabetic ketoacidosis -- insulin -- insulin aspart -- infusions, intravenous -- insulin, short acting; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.13607
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: This study evaluates the clinical efficacy and safety of NovoRapid (insulin aspart) compared to Actrapid™ (human neutral insulin) for diabetic ketoacidosis (DKA). In this retrospective study involving 40 patients, no statistically significant differences were observed between biochemical variables, infusion duration or complications in patients treated with insulin aspart or human neutral insulin. These results support the use of insulin aspart as an effective and safe alternative to human neutral insulin in DKA.